Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Fudan University
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06683846CT.gov Ivonescimab in the Treatment of Multiple Advanced Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Extramammary Paget Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ivocizumab (this asset) | Fudan University | P2 | CCC · 53 |
| ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| mq719 | Memorial Sloan Kettering Cancer Center | P1 | CC |
| Pembrolizumab | Memorial Sloan Kettering Cancer Center | P1 | CC |
Other indications for Ivocizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kidney Angiomyolipoma | — | P2 | CCC · 53 |
| Urachus Cancer | — | P2 | CCC · 53 |
| Neuroendocrine Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENENational Cancer Institute (NCI)CCC
- NivolumabNational Cancer Institute (NCI)CCC
- IpilimumabNational Cancer Institute (NCI)CCC
- mq719Memorial Sloan Kettering Cancer CenterCC
- PembrolizumabMemorial Sloan Kettering Cancer CenterCC
Citation
Floatz Terminal. Ivocizumab in Extramammary Paget Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ivocizumab-extramammary-paget-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →